| scholarly article | Q13442814 |
| P2093 | author name string | Andrew Layton | |
| Wade Aubry | |||
| Robert Lieberthal | |||
| Arnold Willis | |||
| Grant Bagley | |||
| Simon M Willis | |||
| P2860 | cites work | Complications after prostate biopsy: data from SEER-Medicare | Q34029816 |
| Guideline for the management of clinically localized prostate cancer: 2007 update. | Q34629234 | ||
| Markers of field cancerization: proposed clinical applications in prostate biopsies | Q35991148 | ||
| Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies | Q36097736 | ||
| Cost analysis of screening for, diagnosing, and staging prostate cancer based on a systematic review of published studies | Q36176742 | ||
| Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States | Q36767094 | ||
| The epigenetic promise for prostate cancer diagnosis | Q37967574 | ||
| Prostate cancer detection with office based saturation biopsy in a repeat biopsy population | Q39687621 | ||
| Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial | Q39782091 | ||
| The era of personalized medicine in oncology: novel biomarkers ushering in new approaches to cancer therapy | Q41839642 | ||
| Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States | Q43083728 | ||
| Detection rates of cancer, high grade PIN and atypical lesions suspicious for cancer in the European Randomized Study of Screening for Prostate Cancer | Q43547799 | ||
| Budget impact analysis of a new prostate cancer risk index for prostate cancer detection | Q46098777 | ||
| Quantitative, spatial resolution of the epigenetic field effect in prostate cancer | Q46866560 | ||
| Repeat prostate biopsy and the incremental risk of clinically insignificant prostate cancer | Q83151832 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 15-24 | |
| P577 | publication date | 2013-01-01 | |
| P1433 | published in | American health & drug benefits | Q26842282 |
| P1476 | title | Budget impact model: epigenetic assay can help avoid unnecessary repeated prostate biopsies and reduce healthcare spending | |
| P478 | volume | 6 |
| Q43083508 | A panel of DNA methylation markers reveals extensive methylation in histologically benign prostate biopsy cores from cancer patients |
| Q38546671 | Addressing the need for repeat prostate biopsy: new technology and approaches |
| Q33890201 | Cost consideration in utilization of multiparametric magnetic resonance imaging in prostate cancer |
| Q33805477 | Reduced Rate of Repeated Prostate Biopsies Observed in ConfirmMDx Clinical Utility Field Study |
| Q38269155 | The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications |
| Q38775872 | Use of the 4Kscore test to predict the risk of aggressive prostate cancer prior to prostate biopsy: Overall cost savings and improved quality of care to the us healthcare system. |
Search more.